List view / Grid view
Near-infrared spectroscopy (NIRS) is a rapid and non-destructive analytical technique that is important in analysing or profiling both solid and liquid dosage forms, as well as biotechnological products...
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
Pharmaceutical QbD: Omnipresence in the product development lifecycle; Expert View with Kaiser Optical Systems Inc.; and Reinventing commercial biomanufacturing...
In this NIR In-Depth Focus: Monitoring and controlling drug products and manufacturing processes with NIRS; Development of a NIRS method for quantification of a minor polymorphic form; and an Expert View with Metrohm Process Analytics...
Understanding the effect of API changes in pharmaceutical processing; Improving the consistency of MDI drug delivery; and Expert Views with DDF Summit and Eurofins Lancaster Laboratories...
In this Guide to QA/QC Instrumentation, we consider the Sievers M9 series of TOC Analyzers from GE Analytical Instruments, and METTLER TOLEDO’s UV7 Spectrophotometer...
22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group
Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...
The British Pharmacopoeia (BP) is a collection of authoritative and publicly available quality standards for medicines, supported by guidance and additional value-adding information. First published in 1864, the BP has an illustrious history that has been built on quality and continually responds to the needs of stakeholders and users.
The first part of an in-depth article on Quality by Design (QbD), published in European Pharmaceutical Review in December 2016, focused on designing quality in to a pharmaceutical drug product by considering dosage form design, and understanding the importance of active pharmaceutical ingredients’ (APIs’) and excipients’ properties.
In the context of clinical trial data disclosure, since 2010 the regulatory impetus has shifted towards enhanced disclosure obligations, culminating in the publication of a ‘pro-active’ policy on the publication of clinical trial data for medicinal products for human use1 (Policy 0070) by the European Medicines Agency (EMA) in October…
15 February 2017 | By Nicolás Giménez Stamminger, Manager IT Advisory, KPMG Switzerland
KMPG’s Nicolás Giménez Stamminger explains why serialisation is the solution to counterfeit medicines and how to implement a cost-effective serialisation strategy…
13 February 2017 | By Dr Penny Owen, Life Sciences Hub Wales
From government regulation to European trade, Life Sciences Hub Wales chairperson, Dr Penny Owen, looks ahead to the unknown of a post-Brexit world...
10 February 2017 | By Niamh Marriott, Digital Editor
We caught up with Nexeon’s CEO, Will Rosellini, to talk about the Internet of Medical Things - the dangers, the benefits and what the future holds...
8 February 2017 | By Brian White and Paul Taylor, Healthcare Analysts, Cantor Fitzgerald Europe
Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures...
6 February 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Serialisation and Traceability
Pharma serialisation and traceability expert, Pasi Kemppainen, gives us his insights on how to ensure a future-proof and cost-effective strategy
